Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.

Stock Information for Vanda Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vanda Pharmaceuticals Inc.

Vanda Announces Bysanti(TM) NDA Filing; FDA Decision Expected in Early 2026
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025
FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA
Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti(TM) for the Treatments of Acute Bipolar I Disorder and Schizophrenia
Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.